AR103442A1 - Anticuerpos y receptores de antígenos quiméricos específicos de ror1 - Google Patents
Anticuerpos y receptores de antígenos quiméricos específicos de ror1Info
- Publication number
- AR103442A1 AR103442A1 ARP160100120A ARP160100120A AR103442A1 AR 103442 A1 AR103442 A1 AR 103442A1 AR P160100120 A ARP160100120 A AR P160100120A AR P160100120 A ARP160100120 A AR P160100120A AR 103442 A1 AR103442 A1 AR 103442A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdr
- seq
- antibody
- heavy chain
- fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un anticuerpo o un fragmento de unión al antígeno del mismo, caracterizado porque dicho anticuerpo o un fragmento de unión al antígeno comprende una región variable (VH) de la cadena pesada que comprende: una región determinante de complementariedad de la cadena pesada 3 (CDR-H3) que comprende la secuencia de aminoácidos que se muestra en la SEQ ID Nº 22, 29, 35, 45, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 ó 174; o una CDR-H3 contenida en la secuencia de la cadena pesada variable (VH) que se muestra en la SEQ ID Nº 8, 10, 13, 15, 17, 19, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185,186,187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ó 209. Reivindicación 10: El anticuerpo o un fragmento de cualquiera de las reivindicaciones 1 - 9, caracterizado porque la región VH comprende: una región determinante de complementariedad de la cadena pesada 1 (CDR-H1) que comprende la secuencia de aminoácido que se muestra en la SEQ ID Nº 20, 27, 33, 155, 156, 157, 158, 159, 160, 161, 162 ó 163 y/o una CDR-H1 contenida en la secuencia VH que se muestra en la SEQ ID Nº 8, 10, 13, 15, 17, 19, 175, 176, 177, 178,179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190,191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ó 209; y/o una región determinante de complementariedad de la cadena pesada 2 (CDR-H2) que comprende la secuencia de aminoácidos que se muestra en la SEQ ID Nº 21, 26, 28, 34, 164, 165, 166, 167, 168, 169, 170, 171, 172 ó 173 y/o una CDR-H2 contenida en la secuencia VH que se muestra en la SEQ ID Nº 8, 10, 13, 15, 17, 19, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 ó 209. Reivindicación 91: Una proteína de la superficie celular de cadena simple, caracterizada porque comprende el anticuerpo o un fragmento de cualquiera de las reivindicaciones 1 - 90. Reivindicación 99: Un receptor de antígeno quimérico (CAR) caracterizado porque comprende una porción extracelular que comprende el anticuerpo o un fragmento de cualquiera de las reivindicaciones 1 - 97 y un dominio de señalización intracelular. Reivindicación 106: Un ácido nucleico, caracterizado porque codifica el anticuerpo o un fragmento del mismo de cualquiera de las reivindicaciones 1 - 97, el conjugado de la reivindicación 98 o el receptor de antígeno quimérico de cualquiera de las reivindicaciones 99 - 105. Reivindicación 110: La composición de la reivindicación 109, caracterizada porque además comprende un excipiente farmacéuticamente aceptable. Reivindicación 114: El método de cualquiera de las reivindicaciones 112 - 113, caracterizado porque la enfermedad o el trastorno es un cáncer que expresa ROR1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562104664P | 2015-01-16 | 2015-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103442A1 true AR103442A1 (es) | 2017-05-10 |
Family
ID=55272713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100120A AR103442A1 (es) | 2015-01-16 | 2016-01-18 | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20160208018A1 (es) |
EP (2) | EP3245231B1 (es) |
JP (2) | JP6865688B2 (es) |
KR (1) | KR20170128234A (es) |
CN (1) | CN107428833B (es) |
AR (1) | AR103442A1 (es) |
AU (1) | AU2016206457B2 (es) |
CA (1) | CA2973964A1 (es) |
ES (1) | ES2818103T3 (es) |
MX (2) | MX2017009254A (es) |
NZ (1) | NZ733841A (es) |
TW (2) | TWI718118B (es) |
WO (1) | WO2016115559A1 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS |
CN117244076A (zh) | 2015-11-25 | 2023-12-19 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
US11167040B2 (en) | 2015-11-25 | 2021-11-09 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
WO2017136607A1 (en) | 2016-02-02 | 2017-08-10 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
PT3445787T (pt) | 2016-10-07 | 2021-03-15 | Tcr2 Therapeutics Inc | Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão |
CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
IL292352B2 (en) | 2017-03-14 | 2024-03-01 | Juno Therapeutics Inc | Methods of freezing |
KR101938800B1 (ko) | 2017-03-29 | 2019-04-10 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
CN110573177A (zh) | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
TWI804499B (zh) * | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
EP3684408A1 (en) | 2017-09-19 | 2020-07-29 | Massachusetts Institute of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
JP7095078B2 (ja) * | 2017-09-22 | 2022-07-04 | カイト ファーマ インコーポレイテッド | キメラポリペプチド及びその使用 |
WO2019090003A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) |
MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
EP3797122A4 (en) * | 2018-04-18 | 2022-04-20 | Exelixis, Inc. | ANTI-ROR ANTIBODY CONSTRUCTS |
TW202000239A (zh) | 2018-05-09 | 2020-01-01 | 韓商樂高化學生物科學股份有限公司 | 與抗cd19抗體藥物結合物相關之組合物及方法 |
CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
AU2019301147A1 (en) * | 2018-07-10 | 2021-01-21 | Precigen, Inc. | ROR-1 specific chimeric antigen receptors and uses thereof |
CN113260630B (zh) * | 2018-09-20 | 2024-05-24 | 莱蒂恩技术公司 | 用于用抗cd123免疫治疗来治疗癌症的组合物和方法 |
SG11202100935TA (en) | 2018-09-28 | 2021-02-25 | Massachusetts Inst Technology | Collagen-localized immunomodulatory molecules and methods thereof |
PE20212198A1 (es) * | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
JP2022527081A (ja) * | 2019-03-26 | 2022-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t) |
WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
CN114929751A (zh) * | 2019-09-27 | 2022-08-19 | 南京艾美斐生物医药科技有限公司 | Ror1特异性嵌合抗原受体及其治疗应用 |
CA3173981A1 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
AU2021236145A1 (en) | 2020-03-10 | 2022-09-22 | Dana-Farber Cancer Institute, Inc. | Methods for generating engineered memory-like NK cells and compositions thereof |
WO2021195485A1 (en) * | 2020-03-27 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
TW202216776A (zh) | 2020-07-07 | 2022-05-01 | 美商康愈有限責任公司 | Mic抗體及結合劑以及其使用方法 |
CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
US20220227832A1 (en) | 2020-12-21 | 2022-07-21 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
EP4284918A1 (en) | 2021-01-29 | 2023-12-06 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
CA3234822A1 (en) | 2021-10-28 | 2023-05-04 | Suman Kumar VODNALA | Methods for culturing cells expressing ror1-binding protein |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
TW202330619A (zh) * | 2021-12-28 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ror1抗體和抗ror1抗體藥物偶聯物及其醫藥用途 |
WO2023143315A1 (zh) * | 2022-01-29 | 2023-08-03 | 杭州中美华东制药有限公司 | 一种靶向ror1的抗体或其抗原结合片段及其应用 |
US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023250402A2 (en) | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
WO2024008112A1 (en) * | 2022-07-06 | 2024-01-11 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-ror1 antibodies |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
WO2024094159A1 (zh) * | 2022-11-03 | 2024-05-10 | 南京蓬勃生物科技有限公司 | 靶向人源ror1的单域抗体 |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
ES2274823T3 (es) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica. |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
ES2651952T3 (es) | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20050232921A1 (en) | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
AU2003218456A1 (en) | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
EP1680140B1 (en) | 2003-10-16 | 2011-04-20 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
NZ547279A (en) | 2003-10-22 | 2008-04-30 | Keck Graduate Inst | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
SG10201701737XA (en) | 2003-11-06 | 2017-04-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
WO2005097184A2 (en) | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
ES2640216T3 (es) | 2007-12-07 | 2017-11-02 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
BRPI0910509B8 (pt) | 2008-07-10 | 2021-05-25 | Toray Industries | uso do anticorpo, anticorpo e composição farmacêutica |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
WO2012012695A2 (en) | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
US9228023B2 (en) * | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
AU2011336650B2 (en) | 2010-12-01 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
ES2841983T3 (es) | 2011-03-23 | 2021-07-12 | Hutchinson Fred Cancer Res | Método y composiciones para inmunoterapia celular |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
JP6277126B2 (ja) | 2011-08-09 | 2018-02-07 | アセラ・バイオテクノロジーズ・アーベー | ホスホリルコリン(pc)および/またはpcコンジュゲートに結合する抗体 |
ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
BR112014011417B1 (pt) | 2011-11-11 | 2021-10-13 | Fred Hutchinson Cancer Research Center | Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1 |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
KR20150009556A (ko) | 2012-05-03 | 2015-01-26 | 프레드 헛친슨 켄서 리서치 센터 | 증강된 친화성 t 세포 수용체 및 이의 제조 방법 |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
CN109369808B (zh) * | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
EP2968601A1 (en) | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
SG10201803533YA (en) | 2013-10-31 | 2018-06-28 | Hutchinson Fred Cancer Res | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
SG10201804439PA (en) | 2013-12-20 | 2018-06-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
CN111994037A (zh) | 2014-03-26 | 2020-11-27 | 麦格纳车镜美国有限公司 | 使用投射图标的车辆功能控制系统 |
JP6788573B6 (ja) | 2014-04-10 | 2020-12-16 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | メトトレキサートによる選択と組み合わせたSleeping Beautyトランスポゾンによる遺伝子改変T細胞の製造 |
BR112016027912A2 (pt) | 2014-05-29 | 2018-02-20 | Macrogenics, Inc. | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer |
CN106922148B (zh) | 2014-07-29 | 2021-10-15 | 瑟勒提斯公司 | 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体 |
MX2017005344A (es) | 2014-10-27 | 2017-08-15 | Hutchinson Fred Cancer Res | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
WO2017136607A1 (en) | 2016-02-02 | 2017-08-10 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
CN110573177A (zh) | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
CN107557337B (zh) | 2017-09-15 | 2020-06-26 | 山东兴瑞生物科技有限公司 | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 |
PE20212198A1 (es) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
-
2016
- 2016-01-18 WO PCT/US2016/013808 patent/WO2016115559A1/en active Application Filing
- 2016-01-18 AR ARP160100120A patent/AR103442A1/es unknown
- 2016-01-18 AU AU2016206457A patent/AU2016206457B2/en active Active
- 2016-01-18 CN CN201680016204.1A patent/CN107428833B/zh active Active
- 2016-01-18 EP EP16702306.8A patent/EP3245231B1/en active Active
- 2016-01-18 JP JP2017537510A patent/JP6865688B2/ja active Active
- 2016-01-18 CA CA2973964A patent/CA2973964A1/en active Pending
- 2016-01-18 TW TW105101422A patent/TWI718118B/zh active
- 2016-01-18 KR KR1020177022796A patent/KR20170128234A/ko active IP Right Grant
- 2016-01-18 US US14/997,991 patent/US20160208018A1/en not_active Abandoned
- 2016-01-18 TW TW109132171A patent/TW202126682A/zh unknown
- 2016-01-18 EP EP20178573.0A patent/EP3760644A1/en not_active Withdrawn
- 2016-01-18 ES ES16702306T patent/ES2818103T3/es active Active
- 2016-01-18 NZ NZ733841A patent/NZ733841A/en unknown
- 2016-01-18 MX MX2017009254A patent/MX2017009254A/es unknown
-
2017
- 2017-07-13 MX MX2021009151A patent/MX2021009151A/es unknown
-
2018
- 2018-06-04 US US15/997,635 patent/US10889652B2/en active Active
-
2020
- 2020-12-14 US US17/121,549 patent/US11919970B2/en active Active
-
2021
- 2021-01-15 JP JP2021004675A patent/JP2021061857A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2973964A1 (en) | 2016-07-21 |
AU2016206457A1 (en) | 2017-08-03 |
MX2021009151A (es) | 2021-09-10 |
EP3760644A1 (en) | 2021-01-06 |
EP3245231A1 (en) | 2017-11-22 |
TW202126682A (zh) | 2021-07-16 |
US20180265593A1 (en) | 2018-09-20 |
JP2021061857A (ja) | 2021-04-22 |
US20210238309A1 (en) | 2021-08-05 |
JP2018503380A (ja) | 2018-02-08 |
MX2017009254A (es) | 2017-10-12 |
US11919970B2 (en) | 2024-03-05 |
TW201639880A (zh) | 2016-11-16 |
TWI718118B (zh) | 2021-02-11 |
ES2818103T3 (es) | 2021-04-09 |
KR20170128234A (ko) | 2017-11-22 |
JP6865688B2 (ja) | 2021-04-28 |
CN107428833A (zh) | 2017-12-01 |
NZ733841A (en) | 2024-01-26 |
CN107428833B (zh) | 2021-11-02 |
US20160208018A1 (en) | 2016-07-21 |
EP3245231B1 (en) | 2020-08-12 |
AU2016206457B2 (en) | 2021-11-11 |
US10889652B2 (en) | 2021-01-12 |
WO2016115559A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR103442A1 (es) | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
EA201891066A1 (ru) | Антитела к ror1 | |
PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
AR067045A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |